Rhizen Pharmaceuticals is a virtual company that outsources drug development services to globally reputed laboratories. They have a diverse pipeline of proprietary drug candidates targeting various cancers and immune-associated cellular pathways, with their lead candidate being Umbralisib/TGR-1202PI3Kδ Inhibitor for the treatment of haematological malignancies. Rhizen focuses on discovering and developing novel therapeutic options to address significant unmet medical needs in the field of small molecule drugs.